Septic Shock News and Research

RSS

Early use of norepinephrine could benefit patients with sepsis and low blood pressure

Patients with septic shock who were treated with norepinephrine earlier than patients receiving standard care were more likely to have their blood pressure and shock stabilized within six hours of diagnosis, according to a randomized, double-blind, controlled trial published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

4 Feb 2019

New bacteria discovered in the blood of human patients

Two new species of bacteria have been found in the blood of patients in China.

10 Jan 2019

Malnutrition in children with Crohn's disease linked with increased risk of surgical complications

Results of a medical records study of children with Crohn's disease by Johns Hopkins researchers have added substantial evidence for a strong and direct link between malnutrition and increased risk of surgical complications and poor outcomes.

17 Dec 2018

Researchers identify sepsis symptoms that contribute to patient mortality

Using patient records from 210,289 hospital visits between 2013 and 2016, Drexel University researchers have identified the specific symptoms that put patients at the greatest risk of dying from sepsis - and they're not what many clinicians might think.

26 Nov 2018

Predictive model could improve sepsis care

Researchers from MIT and Massachusetts General Hospital have developed a predictive model that could guide clinicians in deciding when to give potentially life-saving drugs to patients being treated for sepsis in the emergency room.

7 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the treatment of sepsis.

15 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

World Sepsis Day

A series of articles and thought leader interviews for World Sepsis Day on the 10th September 2018, aiming to raise awareness and improve understanding.

10 Sep 2018

Raising Awareness of Sepsis

An interview with Dr. Steven Simpson, MD, discussing the importance of raising awareness of the signs and symptoms of sepsis, and how Sepsis Alliance is helping to reduce the number of deaths caused by sepsis in the USA.

10 Sep 2018

People with acute critical illness have increased risk of kidney complications and death

Acute critical illness in people without previous renal disease puts them at risk of kidney complications as well as death, according to a study in published in CMAJ

10 Sep 2018

Avoidable sepsis infections send thousands of seniors to gruesome deaths

Shana Dorsey first caught sight of the purplish wound on her father's lower back as he lay in a suburban Chicago hospital bed a few weeks before his death.

6 Sep 2018

Watch: What is sepsis?

What exactly is sepsis, and why is it so dangerous? Sepsis happens as the body tries to fight off an infection. The body releases chemicals into the bloodstream to battle the invading germs — which can lead to a severe drop in blood pressure. That can damage vital organs and, in severe cases, cause them to shut down.

6 Sep 2018

Researchers discover new protein that controls level of inflammation-inducing molecule

One of the major therapeutic targets for inflammatory diseases is the inflammation-inducing molecule TNF. However, excess levels of TNF cause side effects and can lead to diseases.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Septic Shock News and Research

Early use of norepinephrine could benefit patients with sepsis and low blood pressure

New bacteria discovered in the blood of human patients

Malnutrition in children with Crohn's disease linked with increased risk of surgical complications

Researchers identify sepsis symptoms that contribute to patient mortality

Predictive model could improve sepsis care

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

World Sepsis Day

Raising Awareness of Sepsis

People with acute critical illness have increased risk of kidney complications and death

Avoidable sepsis infections send thousands of seniors to gruesome deaths

Watch: What is sepsis?

Researchers discover new protein that controls level of inflammation-inducing molecule

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News